Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

• Published in: Nature communications Vol. 11; no. 1; pp. 1683 - 12
• Main Authors: Janelidze, Shorena, Stomrud, Erik, Smith, Ruben, Palmqvist, Sebastian, Mattsson, Niklas, Airey, David C., Proctor, Nicholas K., Chai, Xiyun, Shcherbinin, Sergey, Sims, John R., Triana-Baltzer, Gallen, Theunis, Clara, Slemmon, Randy, Mercken, Marc, Kolb, Hartmuth, Dage, Jeffrey L., Hansson, Oskar
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 03.04.2020; Nature Publishing Group; Nature Portfolio
• Subjects: 692/53/2421; 692/617/375/132/1283; Aged; Aged, 80 and over; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - diagnosis; Alzheimer's disease; Basic Medicine; Biomarkers; Biomarkers - cerebrospinal fluid; Brain; Brain - diagnostic imaging; Carbolines - administration & dosage; Cerebrospinal fluid; Contrast Media - administration & dosage; Dementia disorders; Diagnosis, Differential; Diagnostic systems; Feasibility Studies; Female; Fluorine isotopes; Humanities and Social Sciences; Humans; Immunoassay; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Medicinska och farmaceutiska grundvetenskaper; Metabolism; Middle Aged; multidisciplinary; Neocortex; Neurodegenerative diseases; Neurosciences; Neurovetenskaper; Phosphorylation; Positron emission; Positron emission tomography; Science; Science (multidisciplinary); Sweden; Tau protein; tau Proteins - cerebrospinal fluid; tau Proteins - metabolism; Threonine; Tomography; Sweden

Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer’s disease (AD), reflecting abnormal tau metabolism in the brain. Here we investigate the performance of CSF p-tau217 as a biomarker of AD in comparison to p-tau181. In the Swedish BioFIN...